Clinigen Group PLC - Burton On Trent, Staffordshire-based pharmaceutical services - Signs distribution agreement with Deciphera Pharmaceuticals for the supply and distribution of Qinlock into multiple countries around the world.
Qinlock was approved by the European Medicines Agency in November 2021 for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment.
As part of the deal, Clinigen will supply Qinlock into multiple countries where it is not yet commercially available.
Chief Operating Officer Sam Herbert says: "GIST is a complex disease with a high unmet need and this agreement will help to ensure healthcare professionals can obtain compliant access to a critical medicine that is not commercially available in their country."
Company is currently acquisition target of funds managed by Triton Investment Management Ltd. Earlier this month, Clinigen shareholders approved the takeover by the private equity firm, which offered 925 pence per share in cash, valuing Clinigen at GBP1.3 billion. The deal remains subject to antitrust and foreign investment approvals.
Current stock price: 918.16 pence
12-month change: up 15%
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
